The potential for epigenetic analysis of paediatric CNS tumours to improve diagnosis, treatment and prognosis

Annals of Oncology

Volumn 26, Issue 7, 2015, Pages 1314-1324

  Sexton Oates, A ^a,b   MacGregor, D ^a,c   Dodgshun, A ^c   Saffery, Richard ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^c ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

CNS tumour; DNA methylation; Epigenetics; Paediatric

Indexed keywords

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN PATCHED 1; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; SONIC HEDGEHOG PROTEIN; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTOME; UNTRANSLATED RNA; WNT PROTEIN; TUMOR MARKER;

ARTICLE; ATYPICAL TERATOID RHABDOID TUMOR; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER GRADING; CANCER PROGNOSIS; CANCER RISK; CANCER THERAPY; CARCINOGENESIS; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; CHILDHOOD CANCER; CLASSIFICATION; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; DNA METHYLATION; EARLY DIAGNOSIS; EPENDYMOMA; EPIGENETICS; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; GENETIC ASSOCIATION; GLIOMA; HTERT GENE; HUMAN; MEDULLOBLASTOMA; MGMT GENE; MOLECULAR CLASSIFICATION; NEUROECTODERM TUMOR; PILOCYTIC ASTROCYTOMA; PREDICTIVE VALUE; PRIMITIVE NEUROECTODERMAL TUMOR; PRIORITY JOURNAL; PTCH1 GENE; RASSF1A GENE; SENSITIVITY AND SPECIFICITY; SHH GENE; SYSTEMS BIOLOGY; TRANSCRIPTOMICS; WNT GENE; CENTRAL NERVOUS SYSTEM NEOPLASMS; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; MORTALITY; PROGNOSIS; SURVIVAL RATE;

BIOMARKERS, TUMOR; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PROGNOSIS; SURVIVAL RATE;

EID: 84946737014     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv024     Document Type: Article

References (111)

1. Jones D, Kocialkowski S, Liu L et al. Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549: BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma. Oncogene 2009; 28: 2119-2123.
2. Baade P, Youlden D, Valery P et al. Trends in incidence of childhood cancer in Australia, 1983-2006. Brit J Cancer 2010; 102(3): 620-626.
3. Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncol 2012; 14(Suppl 5):v1-v49.
4. Kaderali Z, Lamberti-Pasculli M, Rutka JT. The changing epidemiology of paediatric brain tumours: a review from the Hospital for Sick Children. Child Nerv Syst 2009; 25: 787-793.
5. AIHW. A Picture of Australia's Children 2009. Canberra: Australian Institute of Health and Welfare 2009.
6. AIHW. A Picture of Australia's Children 2012. Canberra: Australian Institute of Health and Welfare 2012.
7. Winick N. Neurocognitive outcome in survivors of pediatric cancer. Curr Opin Pediatr 2011; 23(1): 27-33.
8. Armstrong GT, Jain N, Liu W et al. Region-specific radiotherapy and neuropsychological outcomes in adult survivors of childhood CNS malignancies. Neuro Oncol 2010; 12(11): 1173-1186.
9. Lund LW, Schmiegelow K, Rechnitzer C, Johansen C. A systematic review of studies on psychosocial late effects of childhood cancer: structures of society and methodological pitfalls may challenge the conclusions. Pediatr Blood Cancer 2011; 56(4): 532-543.
10. Louis D, Ohgaki H, Wiestler O et al. The 2007 WHO Classification of Tumours of the Central Nervous System. Acta Neuropathol 2007; 114(2): 97-109.
11. Taylor MD, Northcott PA, Korshunov A et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol 2012; 123(4):465-472.
12. Paugh BS, Qu C, Jones C et al. Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol 2010; 28(18): 3061-3068.
13. Jones C, Perryman L, Hargrave D. Paediatric and adult malignant glioma: close relatives or distant cousins? Nat Rev Clin Oncol 2012; 9(7):400-413.
14. Gerges N, Fontebasso AM, Albrecht S et al. Pediatric high-grade astrocytomas: a distinct neuro-oncological paradigm. Genome Med 2013; 5(7):66.
15. Cage TA, Mueller S, Haas-Kogan D, Gupta N. High-grade gliomas in children. Neurosurg Clin N Am 2012; 23(3): 515-523.
16. Ostrom QT, Gittleman H, Farah P et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro Oncol 2013; 15(Suppl 2):ii1-ii56.
17. Jones DT, Ichimura K, Liu L et al. Genomic analysis of pilocytic astrocytomas at 0.97 Mb resolution shows an increasing tendency toward chromosomal copy number change with age. J Neuropathol Exp Neurol 2006; 65(11): 1049-1058.
18. Jeuken JW, von Deimling A, Wesseling P. Molecular pathogenesis of oligodendroglial tumors. J Neuro Oncol 2004; 70(2): 161-181.
19. Kilday J-P, Rahman R, Dyer S et al. Pediatric ependymoma: biological perspectives. Mol Cancer Res 2009; 7(6): 765-786.
20. Rickert CH, Wiestler OD, Paulus W. Chromosomal imbalances in choroid plexus tumors. Am J Pathol 2002; 160(3): 1105-1113.
21. Korshunov A, Remke M, Werft W et al. Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification. J Clin Oncol 2010; 28(18): 3054-3060.
22. Northcott PA, Hielscher T, Dubuc A et al. Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct. Acta Neuropathol 2011; 122(2): 231-240.
23. Mendrzyk F, Korshunov A, Benner A et al. Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma. Clin Cancer Res 2006; 12(7):2070-2079.
24. Rousseau A, Idbaih A, Ducray F et al. Specific chromosomal imbalances as detected by array CGH in ependymomas in association with tumor location, histological subtype and grade. J Neurooncol 2010; 97(3): 353-364.
25. Korshunov A, Witt H, Hielscher T et al. Molecular staging of intracranial ependymoma in children and adults. J Clin Oncol 2010; 28(19): 3182-3190.
26. Godfraind C, Kaczmarska JM, Kocak M et al. Distinct disease-risk groups in pediatric supratentorial and posterior fossa ependymomas. Acta Neuropathol 2012; 124(2): 247-257.
27. Puget S, Philippe C, De Carli E et al. Use of integrated genomics to identify three high-grade glioma subtypes with distinct genetic profiles, pathway signatures, and clinicopathological features. J Clin Oncol 2010; 28(15).
28. Marko NF, Weil RJ. The molecular biology of WHO grade I astrocytomas. Neuro Oncol 2012; 14(12): 1424-1431.
29. Weber R, Hoischen A, Ehrler M et al. Frequent loss of chromosome 9, homozygous CDKN2A/p14ARF/CDKN2B deletion and low TSC1 mRNA expression in pleomorphic xanthoastrocytomas. Oncogene 2007; 26(7): 1088-1097.
30. Rickert CH, Sträter R, Kaatsch P et al. Pediatric high-grade astrocytomas show chromosomal imbalances distinct from adult cases. Am J Pathol 2001; 158(4):1525-1532.
31. Puget S, Grill J, Valent A et al. Candidate genes on chromosome 9q33-34 involved in the progression of childhood ependymomas. J Clin Oncol 2009; 27(11):1884-1892.
32. Picard D, Miller S, Hawkins CE et al. Markers of survival and metastatic potential in childhood CNS primitive neuro-ectodermal brain tumours: an integrative genomic analysis. Lancet Oncol 2012; 13(8): 838-848.
33. Inda M, Perot C, Guillaud-Bataille M et al. Genetic heterogeneity in supratentorial and infratentorial primitive neuroectodermal tumours of the central nervous system. Histopathology 2005; 47(6): 631-637.
34. Behdad A, Perry A. Central nervous system primitive neuroectodermal tumors: a clinicopathologic and genetic study of 33 cases. Brain Pathol 2010; 20(2):441-450.
35. Biegel JA, Tan L, Zhang F et al. Alterations of the hSNF5/INI1 gene in central nervous system atypical teratoid/rhabdoid tumors and renal and extrarenal rhabdoid tumors. Clin Cancer Res 2002; 8(11): 3461-3467.
36. Hasselblatt M, Isken S, Linge A et al. High-resolution genomic analysis suggests the absence of recurrent genomic alterations other than SMARCB1 aberrations in atypical teratoid/rhabdoid tumors. Genes Chromosomes Cancer 2013; 52(2):185-190.
37. Witt H, Mack SC, Ryzhova M et al. Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell 2011; 20(2):143-157.
38. Pollack IF, Finkelstein SD, Woods J et al. Expression of p53 and prognosis in children with malignant gliomas. New Engl J Med 2002; 346(6): 420-427.
39. Esteller M. Epigenetics in cancer. New Engl J Med 2008; 358(11): 1148-1159.
40. Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer 2004; 4(2): 143-153.
41. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128(4): 683-692.
42. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3(6): 415-428.
43. Portela A, Esteller M. Epigenetic modifications and human disease. Nat Biotechnol 2010; 28(10): 1057-1068.
44. Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nat Rev Genet 2006; 7(1): 21-33.
45. Esteller M. Aberrant DNA methylation as a cancer-inducing mechanism. Annu Rev Pharmacol 2005; 45: 629-656.
46. Rodríguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat Med 2011; 17(3): 330-339.
47. Esteller M, Garcia-Foncillas J, Andion E et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. New Engl J Med 2000; 343(19): 1350-1354.
48. Melguizo C, Prados J, Gonzalez B et al. MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy. J Transl Med 2012; 10(1):250.
49. Reifenberger G, Hentschel B, Felsberg J et al. Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. Int J Cancer 2012; 131(6):1342-1350.
50. Hegi ME, Diserens A-C, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. New Engl J Med 2005; 352(10): 997-1003.
51. Balaña C, Ramirez JL, Taron M et al. O6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1, 3-bis (2- chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme. Clin Cancer Res 2003; 9(4): 1461-1468.
52. Anda T, Shabani HK, Tsunoda K et al. Relationship between expression of O 6- methylguanine-DNA methyltransferase, glutathione-S-transferase π in glioblastoma and the survival of the patients treated with nimustine hydrochloride: an immunohistochemical analysis. Neurol Res 2003; 25(3): 241-248.
53. Paz MF, Yaya-Tur R, Rojas-Marcos I et al. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res 2004; 10(15): 4933-4938.
54. Hegi ME, Diserens A-C, Godard S et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004; 10(6):1871-1874.
55. Kamiryo T, Tada K, Shiraishi S et al. Correlation between promoter hypermethylation of the O6-methylguanine-deoxyribonucleic acid methyltransferase gene and prognosis in patients with high-grade astrocytic tumors treated with surgery, radiotherapy, and 1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-nitrosourea-based chemotherapy. Neurosurgery 2004; 54(2): 349-357.
56. Watanabe T, Katayama Y, Komine C et al. O6-methylguanine-DNA methyltransferase methylation and TP53 mutation in malignant astrocytomas and their relationships with clinical course. Int J Cancer 2005; 113(4): 581-587.
57. Donninger H, Vos MD, Clark GJ. The RASSF1A tumor suppressor. J Cell Sci 2007; 120(18): 3163-3172.
58. Harada K, Toyooka S, Maitra A et al. Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines. Oncogene 2002; 21(27):4345.
59. Chang Q, Pang JC-S, Li KKW et al. Promoter hypermethylation profile of RASSF1A, FHIT, and sFRP1 in intracranial primitive neuroectodermal tumors. Hum Pathol 2005; 36(12): 1265-1272.
60. Inda MdM, Castresana JS. RASSF1A promoter is highly methylated in primitive neuroectodermal tumors of the central nervous system. Neuropathology 2007; 27(4): 341-346.
61. Lindsey JC, Lusher ME, Anderton JA et al. Identification of tumour-specific epigenetic events in medulloblastoma development by hypermethylation profiling. Carcinogenesis 2004; 25(5): 661-668.
62. Herman JG, Merlo A, Mao L et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995; 55(20): 4525-4530.
63. Belinsky SA, Nikula KJ, Palmisano WA et al. Aberrant methylation of p16INK4a is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci USA 1998; 95(20): 11891-11896.
64. McDermott KM, Zhang J, Holst CR et al. p16INK4a prevents centrosome dysfunction and genomic instability in primary cells. PLoS Biol 2006; 4(3):e51.
65. Reynolds PA, Sigaroudinia M, Zardo G et al. Tumor suppressor p16INK4A regulates polycomb-mediated DNA hypermethylation in human mammary epithelial cells. J Biol Chem 2006; 281(34): 24790-24802.
66. Gonzalez-Zulueta M, Bender CM, Yang AS et al. Methylation of the 50 CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 1995; 55(20): 4531-4535.
67. Merlo A, Herman JG, Mao L et al. 50 CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1995; 1(7): 686-692.
68. Frühwald MC, O'Dorisio MS, Dai Z et al. Aberrant promoter methylation of previously unidentified target genes is a common abnormality in medulloblastomas-implications for tumor biology and potential clinical utility. Oncogene 2001; 20(36):5033.
69. Gonzalez-Gomez P, Bello MJ, Lomas J et al. Epigenetic changes in pilocytic astrocytomas and medulloblastomas. Int J Mol Med 2003; 11(5):655.
70. Mühlisch J, Bajanowski T, Rickert C et al. Frequent but borderline methylation of p16 INK4a and TIMP3 in medulloblastoma and sPNET revealed by quantitative analyses. J Neuro Oncol 2007; 83(1): 17-29.
71. Inda M, Muñoz J, Coullin P et al. High promoter hypermethylation frequency of p14/ARF in supratentorial PNET but not in medulloblastoma. Histopathology 2006; 48(5): 579-587.
72. Ebinger M, Senf L, Wachowski O, Scheurlen W. Promoter methylation pattern of caspase-8, P16INK4A, MGMT, TIMP-3, and E-cadherin in medulloblastoma. Pathol Oncol Res 2004; 10(1): 17-21.
73. Fujii H, Biel MA, Zhou W et al. Methylation of the HIC-1 candidate tumor suppressor gene in human breast cancer. Oncogene 1998; 16(16):2159.
74. Ahuja N, Mohan AL, Li Q et al. Association between CpG island methylation and microsatellite instability in colorectal cancer. Cancer Res 1997; 57(16):3370-3374.
75. Melki JR, Vincent PC, Clark SJ. Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia. Cancer Res 1999; 59(15): 3730-3740.
76. Waha A, Waha A, Koch A et al. Epigenetic silencing of the HIC-1 gene in human medulloblastomas. J Neuropathol Exp Neurol 2003; 62(11): 1192-1201.
77. Pritchard JI, Olson JM. Methylation of PTCH1, the patched-1 gene, in a panel of primary medulloblastomas. Cancer Genet Cytogenet 2008; 180(1): 47-50.
78. Diede SJ, Guenthoer J, Geng LN et al. DNA methylation of developmental genes in pediatric medulloblastomas identified by denaturation analysis of methylation differences. Proc Natl Acad Sci USA 2010; 107(1): 234-239.
79. Schwalbe EC, Williamson D, Lindsey JC et al. DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies. Acta Neuropathol 2013; 125(3): 1-13.
80. Hovestadt V, Remke M, Kool M et al. Robust molecular subgrouping and copynumber profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays. Acta Neuropathol 2013; 125(6):913.
81. Mühlisch J, Schwering A, Grotzer M et al. Epigenetic repression of RASSF1A but not CASP8 in supratentorial PNET (sPNET) and atypical teratoid/rhabdoid tumors (AT/RT) of childhood. Oncogene 2005; 25(7): 1111-1117.
82. Schwalbe EC, Hayden JT, Rogers HA et al. Histologically defined central nervous system primitive neuro-ectodermal tumours (CNS-PNETs) display heterogeneous DNA methylation profiles and show relationships to other paediatric brain tumour types. Acta Neuropathol 2013; 126(6): 943-946.
83. Castelo-Branco P, Choufani S, Mack S et al. Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study. Lancet Oncol 2013; 14(6): 534-542.
84. Mueller S, Phillips J, Onar-Thomas A et al. PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome. Neuro Oncol 2012; 14(9): 1146-1152.
85. Lambert SR, Witt H, Hovestadt V et al. Differential expression and methylation of brain developmental genes define location-specific subsets of pilocytic astrocytoma. Acta Neuropathol 2013; 126(2): 291-301.
86. Skiriute˙ D, Vaitkiene˙ P, Ašmoniene˙ V et al. Promoter methylation of AREG, HOXA11, hMLH1, NDRG2, NPTX2 and Tes genes in glioblastoma. J Neuro Oncol 2013; 113(3): 1-9.
87. Carén H, Pollard SM, Beck S. The good, the bad and the ugly: epigenetic mechanisms in glioblastoma. Mol Aspects Med 2012; 34(4): 849-862.
88. Waha A, Felsberg J, Hartmann W et al. Frequent epigenetic inactivation of the chaperone SGNE1/7B2 in human gliomas. Int J Cancer 2012; 131(3): 612-622.
89. Gömöri E, Pál J, Kovács B, Dóczi T. Concurrent hypermethylation of DNMT1, MGMT and EGFR genes in progression of gliomas. Diagn Pathol 2012; 7(8):8-16.
90. Chu S-H, Feng D-F, Ma Y-B et al. Promoter methylation and downregulation of SLC22A18 are associated with the development and progression of human glioma. J Transl Med 2011; 9(1):156.
91. Lindemann C, Hackmann O, Delic S et al. SOCS3 promoter methylation is mutually exclusive to EGFR amplification in gliomas and promotes glioma cell invasion through STAT3 and FAK activation. Acta Neuropathol 2011; 122(2):241-251.
92. Campos B, Warta R, Chaisaingmongkol J et al. Epigenetically mediated downregulation of the differentiation-promoting chaperon protein CRABP2 in astrocytic gliomas. Int J Cancer 2012; 131(8): 1963-1968.
93. Martini M, Pallini R, Luongo G et al. Prognostic relevance of SOCS3 hypermethylation in patients with glioblastoma multiforme. Int J Cancer 2008; 123(12): 2955-2960.
94. Noushmehr H, Weisenberger DJ, Diefes K et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010; 17(5): 510-522.
95. Esteller M, Hamilton SR, Burger PC et al. Inactivation of the DNA repair gene O6- methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 1999; 59(4): 793-797.
96. Blanc J, Wager M, Guilhot J et al. Correlation of clinical features and methylation status of MGMT gene promoter in glioblastomas. J Neuro Oncol 2004; 68(3):275-283.
97. Yu J, Zhang H, Gu J et al. Methylation profiles of thirty four promoter-CpG islands and concordant methylation behaviours of sixteen genes that may contribute to carcinogenesis of astrocytoma. BMC Cancer 2004; 4(1):65.
98. Brell M, Tortosa A, Verger E et al. Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas. Clin Cancer Res 2005; 11(14): 5167-5174.
99. Hassler M, Seidl S, Fazeny-Doerner B et al. Diversity of cytogenetic and pathohistologic profiles in glioblastoma. Cancer Genet Cytogen 2006; 166(1):46-55.
100. Schlosser S, Wagner S, Mühlisch J et al. MGMT as a potential stratification marker in relapsed high-grade glioma of children: the HIT-GBM experience. Pediatr Blood Cancer 2010; 54(2): 228-237.
101. Fassan M, Tassone E, Onisto M et al. MGMT promoter methylation in pediatric high-grade gliomas. Child Nerv Syst 2011; 27(1): 7-8.
102. Lee JY, Park C-K, Park S-H et al. MGMT promoter gene methylation in pediatric glioblastoma: analysis using MS-MLPA. Child Nerv Syst 2011; 27(11):1877-1883.
103. Hamilton DW, Lusher ME, Lindsey JC et al. Epigenetic inactivation of the RASSF1A tumour suppressor gene in ependymoma. Cancer Lett 2005; 227(1):75-81.
104. Michalowski MB, de Fraipont F, Michelland S et al. Methylation of RASSF1A and TRAIL pathway-related genes is frequent in childhood intracranial ependymomas and benign choroid plexus papilloma. Cancer Genet Cytogenet 2006; 166(1):74-81.
105. Alonso ME, Bello MJ, Gonzalez-Gomez P et al. Aberrant CpG island methylation of multiple genes in ependymal tumors. J Neuro Oncol 2004; 67(1-2):159-165.
106. Rousseau E, Ruchoux MM, Scaravilli F et al. CDKN2A, CDKN2B and p14 ARF are frequently and differentially methylated in ependymal tumours. Neuropathol Appl Neurobiol 2003; 29(6): 574-583.
107. Waha A, Koch A, Hartmann W et al. Analysis of HIC-1 methylation and transcription in human ependymomas. Int J Cancer 2004; 110(4): 542-549.
108. Koos B, Peetz-Dienhart S, Riesmeier B et al. O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation is significantly less frequent in ependymal tumours as compared to malignant astrocytic gliomas. Neuropathol Appl Neurobiol 2010; 36(4): 356-358.
109. Buccoliero A, Castiglione F, Rossi Degl'Innocenti D et al. O6-Methylguanine-DNA-methyltransferase in recurring anaplastic ependymomas: PCR and immunohistochemistry. J Chemother 2008; 20(2): 263-268.
110. Mack S, Witt H, Piro R et al. Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature 2014; 506(7489): 445-450.
111. Sturm D, Witt H, Hovestadt V et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 2012; 22(4): 425-437.